No detectable indirect effects of late-onset Cytomegalovirus disease after valganciclovir (VGC) prophylaxis in kidney transplant recipients
Details
Serval ID
serval:BIB_C4E43E8A5380
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
No detectable indirect effects of late-onset Cytomegalovirus disease after valganciclovir (VGC) prophylaxis in kidney transplant recipients
Title of the conference
Abstracts of the 15th International Symposium on Infections in the Immunocompromised Host
Address
Thessaloniki, Greece, June 22-25, 2008
ISBN
1201-9712
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
12
Series
International Journal of Infectious Diseases
Pages
S13
Language
english
Notes
Publication type : Meeting Abstract
Abstract
Background: Cytomegalovirus (CMV) disease remains an important
cause of morbidity after kidney transplantation and has been associated
with acute rejection, graft loss and other indirect effects.
A 3-month course of VGC prophylaxis reduces the incidence of CMV
disease. However, little is known about the indirect effects of lateonset
CMV disease after VGC prophylaxis.
Objective: To evaluate the impact and indirect consequences of
late-onset CMV disease after VGC prophylaxis in kidney transplant
recipients.
Methods: Retrospective analysis of 61 consecutive adult kidney
transplant recipient with positive CMV serology (donor or recipient)
who received VGC prophylaxis for 3 months and completed
a follow-up of at least 2 years post-transplantation. Patients who
developed CMV disease within 1 year after transplantation were
compared to CMV disease-free patients for renal function (plasma
creatinine values) at 1, 6, 12 and 24 months and for the incidence
of graft loss, acute rejection, diabetes, cancer and opportunistic
infections.
Results: 8/61 (13%) patients developed CMV disease at a median of
131 days after transplantation (range: 98-220). The CMV incidence
in D+/R- high risk patients was 6/18 (33%), while it was 2/43 (5%) in
intermediate-risk patients (p < 0.01). All 8 patients were treated
by oral valganciclovir (median 39 days; range: 19-119) with a complete
resolution of CMV disease. As shown in the figure, there was
no difference in creatinine values between the two groups at any
time during follow-up. There was no graft loss, and the incidence
of acute rejection, cancer and opportunistic infections did not differ
between the two groups. The incidence of post-transplant diabetes
was higher (38% vs 15%) in patients with CMV disease, but
this difference was not significant (p = 0.4).
Conclusions: An incidence of 13% of late-onset CMV disease was
observed despite 3 months VGC prophylaxis. However, no indirect
consequences were found. Moreover, therapy of CMV disease by
oral VGC was effective and safe. Larger trials are needed to study
whether late-onset CMV disease is associated with indirect consequences,
as described with early-onset CMV.
cause of morbidity after kidney transplantation and has been associated
with acute rejection, graft loss and other indirect effects.
A 3-month course of VGC prophylaxis reduces the incidence of CMV
disease. However, little is known about the indirect effects of lateonset
CMV disease after VGC prophylaxis.
Objective: To evaluate the impact and indirect consequences of
late-onset CMV disease after VGC prophylaxis in kidney transplant
recipients.
Methods: Retrospective analysis of 61 consecutive adult kidney
transplant recipient with positive CMV serology (donor or recipient)
who received VGC prophylaxis for 3 months and completed
a follow-up of at least 2 years post-transplantation. Patients who
developed CMV disease within 1 year after transplantation were
compared to CMV disease-free patients for renal function (plasma
creatinine values) at 1, 6, 12 and 24 months and for the incidence
of graft loss, acute rejection, diabetes, cancer and opportunistic
infections.
Results: 8/61 (13%) patients developed CMV disease at a median of
131 days after transplantation (range: 98-220). The CMV incidence
in D+/R- high risk patients was 6/18 (33%), while it was 2/43 (5%) in
intermediate-risk patients (p < 0.01). All 8 patients were treated
by oral valganciclovir (median 39 days; range: 19-119) with a complete
resolution of CMV disease. As shown in the figure, there was
no difference in creatinine values between the two groups at any
time during follow-up. There was no graft loss, and the incidence
of acute rejection, cancer and opportunistic infections did not differ
between the two groups. The incidence of post-transplant diabetes
was higher (38% vs 15%) in patients with CMV disease, but
this difference was not significant (p = 0.4).
Conclusions: An incidence of 13% of late-onset CMV disease was
observed despite 3 months VGC prophylaxis. However, no indirect
consequences were found. Moreover, therapy of CMV disease by
oral VGC was effective and safe. Larger trials are needed to study
whether late-onset CMV disease is associated with indirect consequences,
as described with early-onset CMV.
Keywords
,
Web of science
Create date
24/08/2010 17:28
Last modification date
20/08/2019 16:40
Usage data
